Meeting
2013 ASCO Annual Meeting
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
Authors
George Somlo
City of Hope Cancer Center, Duarte, CA
George Somlo , Paul Henry Frankel , Thehang H. Luu , Cynthia Ma , Banu Arun , Agustin Garcia , Tessa Cigler , Gini F. Fleming , Harold A. Harvey , Joseph A. Sparano , Rita Nanda , Helen K. Chew , Timothy Jerome Moynihan , Linda T. Vahdat , Matthew P. Goetz , Arti Hurria , Joanne E. Mortimer , David R. Gandara , Alice P. Chen , Jeffrey N. Weitzel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1024)
DOI
10.1200/jco.2013.31.15_suppl.1024
Abstract #
1024
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
First Author: George Somlo
Poster
2015 ASCO Annual Meeting
![Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>)-associated metastatic breast cancer (MBC).](https://d201v5jt9ylckg.cloudfront.net/156/10671/112102/112102_poster_pv.jpg)
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
First Author: George Somlo
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2015 Genitourinary Cancers Symposium
Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Shalu Pahuja